We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 06, 2020

Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2020 Nov 19;[EPub Ahead of Print], E Zsiros, S Lynam, KM Attwood, C Wang, S Chilakapati, EC Gomez, S Liu, S Akers, S Lele, PJ Frederick, K Odunsi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading